10 July 2015
IntegraGen today announced its sales for the first half 2015. Sales for IntegraGen’s business totaled € 2.6 million as of June 30, 2015, up 1% compared to the first half of 2014. The company also reported that it experienced a substantial growth in new projects during the first half of 2015 increasing by (…) »
08 July 2015
IntegraGen and the Georges Pompidou European Hospital (HEGP) announce the signing of an agreement to develop the use of high-throughput sequencing techniques to improve the care of patients.
01 June 2015
Results from two new studies exploring the role of the microRNA biomarker miR-31-3p in patients with metastatic colorectal cancer were presented during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. The studies reported positive results on the association between miR-31-3p expression and clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with (…) »
05 May 2015
Welcome to the inaugural issue of our newsletter. The goal of IntegraNews is to provide an update on the latest news and events at IntegraGen Genomics. This includes the availability of the latest technologies and molecular testing platforms in our lab and new service offerings.
Click here to download IntegraNews
22 April 2015
Data from two studies reporting results from clinical studies with IntegraGen’s miR-31-3p biomarker is scheduled to be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on May 29 through June 2, 2015.
The first study will report results from research conducted in cooperation (…) »
16 April 2015
Results from a study exploring the role of the microRNA biomarker miR-31-3p in patients with advanced adenocarinoma of the lung were presented during the 2015 European Lung Cancer Conference (ELCC) held in Geneva, Switzerland. The data presented demonstrated that the expression of miR-31-3p is associated with the histological type of the (…) »
10 April 2015
IntegraGen today announced its financial results for the year ended 31 December 2014.
The financial statements were reviewed by the Company’s Board of Directors during a meeting held on April 9, 2015.24 March 2015
The Institut Pasteur and IntegraGen today announced the signing of a partnership agreement making IntegraGen the the operator of sequencing activities for the National Reference Centres (NRC) and microbiological collections of the Institut Pasteur.
18 February 2015
IntegraGen Genomics has announced the launch of GeCo, an advanced genomic consulting service which offers statistical support to help researchers analyze and interpret complex genomic data. IntegraGen will offer researchers access to leading experts in the field of biostatistics and bioanalytics and offer support for the advanced and personalized statistical analysis of genomic (…) »
05 February 2015
IntegraGen has announced a distribution agreement for it’s autism risk assessment test. Genoma SA, a subsidiary of the Espirite group, has obtained the rights to market and distribute the autism genetic predisposition test developed by IntegraGen outside the United States.
